BiotechTube

MBX 4291 + Placebo

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity

Conditions

Obesity

Trial Timeline

Sep 3, 2025 → May 30, 2026

NCT ID
NCT07142707

About MBX 4291 + Placebo

MBX 4291 + Placebo is a phase 1 stage product being developed by MBX Biosciences for Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07142707. Target conditions include Obesity.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07142707Phase 1Recruiting

Competing Products

20 competing products in Obesity

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
52
MK0557MerckPhase 3
77
AMG 786AmgenPhase 1
32
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
52
TirzepatideEli LillyPhase 2
52
exenatide + PlaceboEli LillyApproved
85
BrenipatideEli LillyPhase 1
33
Orforglipron + PlaceboEli LillyPhase 3
77
TERN-601Terns PharmaceuticalsPhase 2
49
PG-102Rani TherapeuticsPhase 1
25
Orforglipron + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide + PlaceboEli LillyPhase 1
33
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
52
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
33
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
44
TirzepatideEli LillyApproved
85
Adenosine + RegadenosonAstellas PharmaPre-clinical
23
Micafungin + MicafunginAstellas PharmaApproved
85
MicafunginAstellas PharmaApproved
85

Other Products from MBX Biosciences

MBX 2109Phase 2
47
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionPhase 2
47
MBX 1416 (INN imapextide)Phase 2
47
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)Phase 1
28
MBX 2109 (Part A) + MBX 2109 (Part B) + PlaceboPhase 1
28